



A New **Weapon** in the War on Cancer

June 2023

Safe Harbor and Forward-Looking Statements



Intensity Therapeutics, Inc. (the "Company" or "we") has filed a registration statement, including a preliminary prospectus, with the U.S. Securities and Exchange Commission (the "SEC") (File No. 333-260565) in connection with the offering to which this presentation relates. Sales of the securities of the Company offered pursuant to the registration statement may not be made or offers for such securities accepted prior to the registration statement becoming effective. Before you invest, you should read the registration statement, the preliminary prospectus included within the registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You can obtain a copy of the preliminary prospectus for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Company will arrange to send you the preliminary prospectus, which you may request by emailing jwesolowski@intensitytherapeutics.com.

This presentation may not be reproduced, forwarded to any person or published, in whole or in part. The Company is not soliciting offers to buy securities of the Company in any jurisdiction where the offer or sale is not permitted. This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development and regulatory status of our product candidates, such as statements with respect to our lead product candidate INT230-6, and the timing of clinical trials and data from those trials for our product candidates, and our discovery programs that may lead to our development of additional product candidates, the potential utility of our technology and therapeutic potential of our product candidates, the potential commercialization of any of our product candidates, and the sufficiency of our cash resources. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to: whether we will be able to successfully conduct Phase 1, 2 or 3 clinical trials for INT230-6, whether we complete other clinical trials for our product candidates, whether we receive results from our clinical trials on our expected timelines, or at all, whether our cash resources will be sufficient to fund our foreseeable and unforeseeable operating expenses and capital expenditure requirements on our expected timeline, whether the COVID-19 pandemic impacts our operations, and other factors included in the "Risk Factors" section of the Company's filings with the SEC in the future. Any of these outcomes could cause our actual results to differ from those contained in the forward-looking statements of the Company's filings with the SEC.

The forward-looking statements contained in this presentation reflect our current views as of the date of this presentation with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. The Intensity Therapeutics, Inc. name and logo are our trademarks. We also own the service mark and the registered U.S. trademark for DfuseRx. The trademarks, trade names and service marks appearing in this presentation are the property of the Company. We have omitted the ® and ™ designations, as applicable, for the trademarks named in this presentation.

IPO Offering Summary



Issuer	Intensity Therapeutics
Exchange / Symbol	• Nasdaq Capital Markets / INTS
Offering Type	• Initial Public Offering
Shares Outstanding Pre-Offering:	• 7,534,954 shares
Shares Offered	• 3,250,000 of common stock, or 3,737,500 shares of common stock if underwriters exercise their over-allotment option in full (100% Primary)
Price Range Per Share	• \$4.00 to \$5.00
Base offering at range midpoint	• \$14,625,000
Over-allotment Option	• 15% (100% Primary)
Use of Proceeds	• Advance and Expand Clinical and Preclinical Development Programs • For working capital and other general corporate purposes
Lock-up	• 180 days for each of our directors and officers and stockholders who own 5% or more of our outstanding common stock
Underwriters	• The Benchmark Company, Freedom Capital Markets

Investment Highlights



- Novel Approach to Immuno-Oncology with First-in-Class Compound that causes cancer cell death leading to an immune response for indications with high unmet medical need
- Multiple Late-Stage Pipeline Programs in the Clinic across metastatic and presurgical settings with multiple near-term inflexion points
- Experienced Leadership Team from Emisphere, Roche and Bristol Myers; CEO has public company as well as biopharma development and commercial experience
- Robust IP portfolio, Platform validated through multiple Industry, government and university hospital partnerships
- De-risked and cost-efficient business model structured to create significant value

Platform Validated by World Leading Partners



RESEARCH



CLINICAL TRIAL SITES



Management Team: Extensive Oncology and Drug Development Experience Veteran Operators with Public Company and IPO Experience



Lewis H. Bender, MIT ChE, MS, MA, MBA
Founder, CEO

- Drug delivery expertise Preclinical through Phase 3
- Public biotech company CEO experience



James M. Ahlers
Executive Vice President - Corporate Finance
• 25 years, multiple transactions
• Titan Pharmaceuticals, IPO



Brian Schwartz, MD
Clinical Development



John Wesolowski, MBA, CPA
Chief Financial Officer, Principal Accounting Officer and Controller



KEY MANAGEMENT

- Ian Walters**
Medical Advisor
- Steve Innaimo**
Project Management
- Rebecca Drain, Doranne Frano**
Regulatory & Quality
- Rita Cooney PH.D.**
Analytical Chemistry
- Karen Du**
Clinical Operations
- Joseph Bernadino, George Klein**
Manufacturing



BOARD OF DIRECTORS

Daniel Donovan
CEO Rare Life



Emer Leahy, Ph.D.
CEO Psychogenics



Mark A. Goldberg, MD
Former President & COO of PAREXEL



Lewis H. Bender
CEO Intensity




Multiple Late-Stage Pipeline Programs

Clinical Programs Across Metastatic and Presurgical Settings



Multiple Ongoing Phase 2 Studies or Cohorts; Phase 3 Programs Designed and Discussed with FDA



Total available markets for first indications

- 287,850 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S. during 2022
- About 1 in 8 U.S. women (about 13%) will develop invasive breast cancer over the course of her lifetime.
- 12,000 people in the U.S. and 1,150 in Canada are diagnosed with soft tissue sarcomas each year

7

First Two Clinical Market Opportunities



• Phase 3 programs - important market opportunities:

Metastatic sarcoma:


- 157,000 patients in US;
- 12,000 new cases per year (6,000 deaths); (US)
- *Estimated annual revenue per patient based on phase 2 use*

Presurgical Breast cancer : *First accelerated approval endpoints, then full approval*

- INT230-6 with Standard of Care (SOC) chemotherapy: 30,000 patients US
- w/out chemotherapy: 60,000 Large tumor cases; (US) INT230-6 vs. no treatment (current SOC)

8

- **Designed for intratumoral (IT) use in the fatty environment of a tumor;**
Drug is 100% water-based, scaled-up, stable, & reproducible
- **Product Candidate: INT230-6 – Uses two proven, commercial anti-cancer agents**
Cisplatin and Vinblastine Sulfate; both drugs kill cancer directly
And cause anti-cancer immune activation via different mechanisms
- **Novel diffusion enhancer (SHAO)**



- Enables the drugs to become soluble in fat and water
- Disperses throughout the tumor and diffuse into cancer cells

9

Our Delivery Technology Is Based on a Proven Science Used For Oral Delivery of Proteins



EMISPHERE WAS ACQUIRED BY NOVO NORDISK FOR \$1.8 BILLION

- Technology First Developed for Oral delivery of Protein (Semaglutide); Tablet Product (Rybelsus)
- Intensity's **ISSUED** patents claim use with therapeutic agents for intratumoral delivery
- Intensity has patent protection in 37 countries

Intensity's mechanism: direct killing leading to immune activation




Image from January 2018 Tuberculosis and Respiratory Diseases 81(1):29.

Issues with current systemic therapies:

- Drugs do not reach areas away from blood vessels
- Tumors can exclude T-cells
- Tumors prevent immune recognition

Our solution:

- Tumor saturated with cytotoxics, dies; **cancer cells intact**
- Large quantities of antigen are released to immune cells
- Tumor now favorable to T-cell influx

10

INT230-6: A Unique Anti-Cancer Therapy


A Water Solution That Kills Fatty or Stromal Tumors and Does Not Harm Healthy Tissue




Human pancreatic cancer in mouse model

*Tumors contain high percentages of fat and are under high pressure

CYTOTOXICS DRUG + dye in water



INT230-6 + dye in water



Dose is set by a tumor's volume or diameter

Published 11

Design: Randomized, Placebo Controlled Phase 2 Window Trial In Presurgical Breast Cancer (BC): The INVINCIBLE Study



Patients Enrolled: 91 –Complete

INT230-6 Randomized to either no treatment or saline injection

- **Site:** Ottawa Hospital
- **Investigator:** Dr. Angel Arnaout
- **Objectives:** Cause sufficient tumor necrosis prior to surgery to activate the immune system and determine INT230-6 safety presurgically
- **Final Goal:** Reduce the risk of disease recurrence

Our clinical results have been selected for Spotlight Oral Podium Presentation at: The San Antonio Breast Cancer Society (SABCS) annual meeting December 2022:

12

Phase 2 INVINCIBLE Study: INT230-6 Achieves Significant Cancer Necrosis with 1 or 2 Doses




Patient #14:
3.9 cm invasive ductal cancer:: 2 injections



Final Pathology (significant necrosis ~85%)

Patient #20:
4.4 cm invasive lobular cancer: 1 injection



Final Pathology (significant necrosis ~95%)
cancer is mostly ghost cells

Tumor death is dependent on total dose given per treatment and observed in multiple types of breast cancers

13

INT230-6 had Favorable Safety in the Presurgical BC Setting



- No surgery was delayed or cancelled
- No surgical procedure was altered
- No cosmetic differences noted
- Mean wait time to surgery: 24 days (range 14-34 days) – normal timeframe
- 89% of adverse events were grade 1; all resolved within 7 days
- **Patient interest in the drug and acceptability was high; accrual was rapid**

Pre vs. Post treatment (part1)

- In tumor: **increase in abundance of CD4+, CD8+, naïve T, B and NK T cells**
- In tumor microenvironment: **increase in CD8 T, CD4 T, naïve and B cells**
- Over 200 immune cell genes activated

14

Study: Necrosis Efficacy and Phase 2/3 Study Design

Major pathological response (MPR) defined as $\leq 10\%$ residual cancer remaining in tumor

- MPR was 6% overall in study with **14.3% in tumors >2.9 cm** compared to control (0%) $p=0.042$

Pathological complete response (pCR) defined as 100% elimination of viable cancer (tumor + nodes)

pCR was 9.5% in subjects with tumors >2.9 cm in diameter

Design of Phase 3 Program in the larger T2, T3, T4 sized tumors

INT230-6 + Standard of care (SOC is chemo/pembro) in TNBC and/or HER2+ vs. SOC

- **Accelerated approval** using Pathological Complete Response (pCR);
 - Data 4 months post enrollment
- **Full approval** showing event free survival (EFS);
 - Data 3 years post enrollment

15

Attacking the Tumors – Sparing the Patient

IT-01 Phase 1 / 2 Study in Metastatic Disease –Enrollment Complete

ENROLLED: 110

Patients whose disease had progress after treatment with all approved therapies for their cancer, over 25 types of solid tumor types: **Database now locked**

INT230-6 alone (64 patients)

With Keytruda (30 patients) (includes 2 who finished monotherapy)



With Yervoy (18 patients)

- Injections up to 6 in a session into lung, liver, peritoneum, pancreas, breast, limbs, lymph, skin, muscles
- Dosed started with 5 mL once per month. Current dose 175 mL every two weeks.

Intensity's results have been selected for Discussant Oral Podium Presentations at:

- The Annual American Society of Clinical Oncology: ASCO (2)
- The Annual Society for the Immunotherapy of Cancer: SITC
- The Annual Connective Tissue Society (sarcoma): CTOS (2)

16



INT230-6

>95% of the active agents remain in the tumor relative to the drugs given IV

The retention is independent of the cancer type, location or size

Plasma cisplatin levels cannot be measured - only (non-toxic) platinum

At 1 hour the plasma levels of a 5.4 mg IV dose of vinblastine is estimated at ~200 ng/mL: [Link et al](#)


Most common drug related adverse events are mild or moderate pain, fatigue and nausea; Only 11% are grade 3

In Metastatic Disease injected Tumors Shrink in Volume Over Time


Shrinkage of uninjected tumors is observed

Tumors may appear longer prior to shrinking

Pre-treatment: 55.65 mm x 32.48 mm
September 2020



Post-treatment: 47.5 mm x 18.78 mm
March 2021




A scan of a monotherapy injected sarcoma tumor highlights tumor regression

Longest diameter declines 15%, whereas 2nd longest diameter declines 42%

Using WHO Criteria: **Partial Response**


Using RECIST Criteria: **Stable Disease**

Immune Activation Achieved in Non-immunogenic Cancers




After 2 doses of INT230-6 alone there is an increased anti-cancer immune cell influx into the tumor

Ovarian cancer



Liposarcoma

Survival Increases with Higher Dose Relative to the Patient's Tumor Burden




Monotherapy: 19 different cancers

An exploratory analysis of dose relative to a subject's incoming total tumor burden (TTB) was performed.

In Sarcoma Median Overall Survival Increases with INT230-6 Alone or with Yervoy) Compared to a Synthetic Control



Kaplan Meier estimates sarcoma (Data as of 9/22)



Dose relative to incoming total tumor burden (TTB) show increased survival with higher drug loadings

Favorable hazard ratios (HR) for sarcoma subjects administered INT230-6 compared to control

Abscopal responses seen were primarily in subjects dosed to $\geq 40\%$ total tumor burden

	Synthetic Control (Subbiah data)	INT230-6 all	INT230-6 >40% TTB	INT230-6 + IPI
Median overall survival, CI	205 days	649 (195, 1352)	715 (649, 1352)	Not reached median follow-up: 345 days

Synthetic control created based on data from Subbiah, V, Scientific Reports | 6:35448

21

Phase 3 Trial Design For INT230-6 In Soft Tissue Sarcoma (STS)



Expected to Offer Survival Improvement compared to Current 2nd / 3rd Line SOC

HR: 0.65

Overall survival (OS):
14.0 months Control
21.5 months INT230-6

- ≥ 18 years
- ECOG PS ≤ 2
- Locally recurrent, inoperable or metastatic Soft Tissue Sarcomas
- 2L/3L
- measurable disease by RECIST 1.1
- at least one target tumor for injection

Must have had doxorubicin
2:1
n = up to 332

INT230-6 - Monotherapy

- INT230-6 q2 weeks x 5 doses
- Maintenance q9 weeks x 22 months

Standard of Care

- Pazopanib: 800 mg PO qD
- Trabectedin: 1.5 mg/M² BSA as a 24 hour IV infusion q3 weeks
- Eribulin: 1.4 mg/M² BSA IV on Days 1 and 8 q3 weeks

- Primary Endpoint:**
- OS
- Secondary Endpoints:**
- Safety
 - QoL
 - OS for leiomyosarcoma
 - OS for liposarcoma

Enrollment: 12 to 15 months
First look: ~12 months post

Data readout at 80% of events

22

Conclusions



- **INT230-6 represents a new treatment approach to solid tumors (immunological cell killing) both in the metastatic and presurgical (neoadjuvant) settings**
 - Strong interest from: academic hospitals, major clinical oncology societies, big pharma and government
- INT230-6 has:
 - induced significant necrosis in large tumors following a single dose
 - Immune activation observed of non-immunogenic cancer types
 - Shown favorable safety and promising increased survival efficacy

23

MULTIPLE UPCOMING KEY CLINICAL MILESTONES



MILESTONES	EXPECTED TIMING
Report Phase 2 INVINCIBLE Study data (Part 1)	Q4 2022 ✓
Report Phase 2 INVINCIBLE Study Systemic Immune Response Data (Part 2)	Q2 2023
Regulatory filings regarding phase 3 programs	Q2 2023
Report Sarcoma Phase 2 Data	Q2 2023
Report Final pembrolizumab Phase 2 Combination data	Q4 2023
Multiple manuscripts for peer-review submissions to	Throughout 2023/24
Initiate randomized phase 2/3 study in neoadjuvant BC with potential accelerated approval endpoint	Q423/Q1'24*
Initiate randomized phase 3 study in soft tissue sarcoma (overall survival endpoint)	Q423/Q1'24*
Complete Enrollment of Phase 2/3 neoadjuvant BC phase 2/3 study for Accelerated Approval	2024*
Potential phase 2/3 neoadjuvant BC readout for accelerated approval NDA submission	2024*
Complete Enrollment of Phase 3 sarcoma study	1H 2025

* Pending financing

24

- Novel Approach to Immuno-Oncology with First-in-Class Compound that causes cancer cell death leading to an immune response for indications with high unmet medical need
- Multiple Late-Stage Pipeline Programs in the Clinic across metastatic and presurgical settings with multiple near-term inflexion points
- Experienced Leadership Team from Emisphere, Roche and Bristol Myers; CEO has public company as well as biopharma development and commercial experience
- Robust IP portfolio, Platform validated through multiple Industry, government and university hospital partnerships
- De-risked and cost-efficient business model structured to create significant value

25

INTENSITY THERAPEUTICS

**A NEW WEAPON
IN THE WAR ON CANCER**

Contact

Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com

Thank you!

26

Intensity Therapeutics

A New Weapon In The War On Cancer

Appendix slides

Randomized, Placebo Controlled Phase 2 Trial In Presurgical Breast Cancer (BC): The INVINCIBLE Study


Part 1: Safety and dose ranging – Completed: Study Investigator: Dr. Angel Arnaout Ottawa Hospital Research Institute

Open-label 2:1 randomized study of 29 patients. Treatment arm patients given up to 3 doses of INT230-6 injected weekly prior to breast surgery, at a dose based on longest diameter. The control arm patients receive no treatment.

Part 2 (61 Patients) Enrolled

Double blind; Sham IT Control

- ≥ 18 years
- Female patients with newly diagnosed invasive BC
- Treatment naïve, awaiting surgery.
- Tumor ≥ 1.5 cm
- Bloom Richardson grade ≥2
- Invasive ductal or lobular carcinoma,



Hypothesis

Intratumorally INT230-6 is superior to no treatment or placebo saline injection as measured by key endpoints

Key endpoints

- Residual Cancer burden (% necrosis), major pathological reduction
- Overall safety of the drug
- Change in the proportion of patients achieving a reduction in the proportion of cells staining positive for proliferation

Other important endpoints

- Tumors treated with INT230-6 demonstrate an increase in immune cells (CD4 & CD8-T-cells) within the tumor and blood
- Assess cell death pathways

ClinicalTrials.gov Identifier: NCT#04781725

IT Injections were All Done by Surgeons (using a low-cost US device)

GOAL: Cause Necrosis prior to surgery to activate the immune system for better event free survival

PHASE 2 INVINCIBLE Study:

INT230-6 Achieves Significant Cancer tumor necrosis Presurgically with One Injection in Multiple Types of Breast Cancer




Patient #32 (PART II):

3.3 cm invasive ductal cancer: Grade 2, ER+PR+Her2-
1 injection (13 mls 12 days preop)

Tumor post surgery


.....
Tumor Extent

.....
Extent of
Necrosis
within Tumor



Gross: 100% necrosis

Histology: Sheet like necrosis going to and beyond tumor border



43

INT230-6 Phase 1 / 2 Clinical trial: Case study

Deep Squamous cell carcinoma patient recommended for arm and shoulder amputation in January 2018



PRIOR HISTORY: Failed 2 surgeries, radiation, chemotherapy

- Two large deep tumor nodules in muscle of left arm
- Failure on all prior therapy

AFTER INT230-6:


- Increase in necrosis and inflammation of tumor
- No RECIST progression
- Blood shows increase in:
 - T-cells (CD4+ and CD8+)
 - Macrophages
 - TNF-a

Results observed despite minimal dosing and non-optimal drug-to-tumor ratios –
Patient remains alive today with arm/shoulder

Darker contrast indicates increased tumor necrosis





March 18, 2018



May 15, 2018

RECIST Metrics Are Inadequate to Capture Efficacy

Diameters Increase While Volumes Decline – Data For Sarcoma Subjects



The lack of correlation between a tumor's diameter and volume indicates that RECIST IS unreliable for IT INT230-6 as a metric of efficacy

Drug is absorbed and immune cells infiltrate


Changes in a tumor longest diameter over time and the tumor's corresponding volume change calculated from 3 dimensions using the modified ellipsoid formula. Each line represents an injected tumor from a subject receiving either INT230-6 with or without ipilimumab. Tumors diameters having a size increase or that were stable often shown a decrease in volume.

Phase 2 INVINCIBLE Study: INT230-6 Achieves Immune Activation in Early Breast Cancer prior to surgery

Pre vs. Post treatment


- In tumor: increase in abundance of CD4 T naïve and B and NK cells
- In tumor microenvironment: increase in CD8 memory T, CD4 naïve and B cells
- Over 200 immune related genes activated post drug treatment

Relative abundance levels of immune cells present in the tumor compared to current standard of care (no treatment controls)




Each bar demonstrates the immune cell abundance in a patient separated by BC subtype.

Survival Increases with Higher Dose Relative to the Patient's Tumor Burden



Monotherapy: 19 different cancers

An exploratory analysis of dose relative to a subject's incoming total tumor burden (TTB) was performed.



Combination: 7 cancer types primarily; pancreatic, colon, bile duct, triple negative breast cancer

mOS not yet reached with 143 days of median follow up